Novartis AG stock gains momentum on SIX Swiss Exchange amid steady SMI performance and upcoming Q1 earnings

The Novartis AG stock (ISIN: CH0012005267) showed solid gains on March 24, 2026, climbing up to 0.7% on the SIX Swiss Exchange in CHF, positioning it as a top performer in the SMI index. With analyst EPS forecasts at 8.81 USD for 2026 and Q1 results due April 28, US investors eye pipeline strength in a volatile pharma sector.

The Novartis AG stock demonstrated resilience on March 24, 2026, posting gains throughout the trading session on the SIX Swiss Exchange. Shares rose as much as 0.7% to 116.90 CHF by mid-morning, reaching intraday highs of 117.08 CHF, and closed stronger at around 116.84 CHF with 0.6% upside. This performance placed the stock among the leaders in the Swiss Market Index (SMI), which hovered near 12,455 points amid broader European market stabilization. Trading volume exceeded 1 million shares by late afternoon, signaling sustained investor interest in the Swiss pharma giant.

As of: 25.03.2026

Dr. Elena Voss, Senior Pharma Equity Analyst: Novartis AG exemplifies defensive growth in biotech, where pipeline durability meets global reimbursement challenges in an era of pricing pressures.

Recent Trading Dynamics on SIX Swiss Exchange

On the SIX Swiss Exchange, the Novartis AG stock opened at 116.98 CHF on March 24, 2026, and quickly built momentum. By 09:28 CET, it had advanced 0.7% to 116.90 CHF, with 133,439 shares exchanged in the morning session. Momentum carried into midday, where shares hit 116.86 CHF up 0.6%, supported by 509,495 shares traded by 12:28 CET. Afternoon trading saw further firmness, with the stock at 116.84 CHF up 0.6% by 16:28 CET and cumulative volume surpassing 1,050,791 shares.

This upward trajectory reflects broader SMI strength, as the index stabilized around 12,474-12,515 points. The Novartis AG stock outperformed many peers, underscoring its role as a defensive play in pharmaceuticals. Currently, it trades 10.76-12.12% below its 52-week high of 131.00 CHF set on February 27, 2026, but 30.59-30.62% above the 52-week low of 81.10 CHF from April 10, 2025—all on SIX Swiss Exchange in CHF.

These movements occur against a backdrop of European market recovery, with investors seeking stability in healthcare amid macroeconomic uncertainty. For Novartis, operational consistency in key franchises like immunology and cardiology drives this appeal.

Analyst Expectations and Earnings Outlook

Analysts project Novartis to report EPS of 8.81 USD for full-year 2026, reflecting confidence in revenue growth from blockbuster drugs. Q1 2026 results are slated for release on April 28, 2026, with Q1 2027 tentatively set for April 27, 2027. These forecasts hinge on sustained demand for core products amid patent cliffs and generic competition.

In the pharma sector, Novartis stands out for its diversified portfolio spanning cardiovascular, immunology, neuroscience, and oncology. Recent mentions include fresh study results in dermatology, bolstering pipeline credibility. UBS AG recently issued a neutral rating, balancing growth potential against valuation concerns.

Strategic Focus in Pharma Pipeline

Novartis AG prioritizes innovative therapies, with recent dermatology study results highlighting potential new approvals. This aligns with sector trends where pipeline data drives stock volatility. The company's operating model emphasizes high-margin specialties, reducing exposure to commoditized generics.

Key franchises include Entresto for heart failure and Cosentyx in immunology, both generating robust sales growth. Oncology remains a growth engine via radioligand therapies, positioning Novartis for long-term expansion. US investors benefit from Novartis' significant North American revenue, often exceeding 40% of total sales.

Recent trading gains on SIX Swiss Exchange in CHF underscore market approval of this strategy. As peers face biosimilar erosion, Novartis' R&D productivity differentiates it.

US Investor Relevance in a Global Context

For US investors, the Novartis AG stock offers defensive exposure to global pharma via ADRs or direct access through brokers supporting SIX Swiss Exchange trading in CHF. The firm's heavy US market presence, including partnerships and reimbursement dynamics under Medicare, ties performance to domestic policy shifts.

With EPS forecasts in USD, valuation comparisons to US peers like Eli Lilly or Pfizer become straightforward. Novartis' dividend yield and buyback programs enhance appeal for income-focused portfolios. Amid US election cycles and drug pricing debates, Novartis' diversified revenue mitigates single-market risks.

Current SMI outperformance signals broader healthcare rotation, relevant for US portfolios diversifying beyond Nasdaq volatility.

Positioning Within the SMI and Broader Market

As a core SMI constituent, Novartis AG influences index futures and derivatives trading. Recent sessions showed aligned strength, with SMI levels supporting 12,400-12,500 ranges. Mini-futures data indicates hedging activity around these levels, indirectly bolstering large-cap pharma like Novartis.

European stabilization contrasts US market choppiness, making Novartis a currency-hedged play on healthcare resilience. Trading on SIX Swiss Exchange in CHF provides natural hedge against USD strength.

Risks and Open Questions Ahead

Despite gains, Novartis faces patent expirations on legacy drugs, pressuring margins. Regulatory hurdles for new launches, especially in oncology, pose approval risks. Generic competition in emerging markets could erode volumes.

Macro factors like Swiss franc appreciation impact reported earnings in CHF on SIX Swiss Exchange. Upcoming Q1 results on April 28, 2026, will test guidance delivery. UBS neutral rating highlights balanced risk-reward.

Geopolitical tensions affecting supply chains remain a watchpoint for global pharma operations.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.